Vantage Reports
Drawing on Evaluate data, Vantage reports provide an in-depth view on trends in the biotech, pharma and medtech sectors. Our special reports also provide a detailed look at some of the industry's hottest topics.
H1 Round Up: The haves and the have-nots
Starting 2023 in a rut, biopharma share prices sparked back to life in Q2, with a $141bn boost to the valuation of companies in the Evaluate Vantage universe. Yet, this…
H1 Round Up: The haves and the have-nots
Starting 2023 in a rut, biopharma share prices sparked back to life in Q2, with a $141bn boost to the valuation of companies in the Evaluate Vantage universe. Yet, this…
ADA/EASL eBook
June saw the coming together of leading physicians, scientists, and healthcare professionals at two key metabolic conferences: ADA 2023 and EASL 2023. These meetings…
ADA/EASL eBook
June saw the coming together of leading physicians, scientists, and healthcare professionals at two key metabolic conferences: ADA 2023 and EASL 2023. These meetings…
ASCO 2023 Round Up
The Evaluate Vantage team are back from the 2023 ASCO Annual Meeting in Chicago, where we've been reporting on all the big data drops and breakthroughs in cancer…
ASCO 2023 Round Up
The Evaluate Vantage team are back from the 2023 ASCO Annual Meeting in Chicago, where we've been reporting on all the big data drops and breakthroughs in cancer…
Biopharma Dealmaking In 2023: The Story So Far
Bio International marks the almost-halfway stage of the year. Representatives from big pharma, single-asset biotechs and everyone in between come together to meet, learn…
Biopharma Dealmaking In 2023: The Story So Far
Bio International marks the almost-halfway stage of the year. Representatives from big pharma, single-asset biotechs and everyone in between come together to meet, learn…
Pharma’s Biggest Spenders 2022 Infographic
As several of the big 11 pharma companies dialled back on acquisitions, the collective bill for M&A and R&D activities among this cohort took a dip for the second…
Pharma’s Biggest Spenders 2022 Infographic
As several of the big 11 pharma companies dialled back on acquisitions, the collective bill for M&A and R&D activities among this cohort took a dip for the second…